BioSpace News Archive

The European Investment Bank today agreed a EUR 30 million facility to support investment by Dublin based biotech company, Nuritas, to further increase and accelerate development of artificial intelligence and DNA analysis to improve global healthcare.

In today’s diagnostic environment, innovations continue at a rapid pace, with emerging molecular diagnostic manufacturers facing increased challenges in meeting complex quality standards, affordability and delivery performance

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) and fruquintinib in combination with checkpoint inhibitors.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS)

Franek Technologies, Inc. is the leader in Laboratory Power Protection Systems (LPS/UPS), Surge Protector aka Battery Backup Power.

Common Sensing, developer and manufacturer of injectable medicine hardware and software tools, announced the appointment of Kevin Schmid as Chief Executive Officer.

Advancements in laser technologies over the years have contributed to various applications of cosmetic treatments, contributing to the growth of the global photorejuvenation equipment market.

intilaris LifeSciences has been providing optimized clinical development services to the global pharmaceutical companies for many years.

Synbal, Inc., a biotechnology company developing non-viral, cell-based gene therapy candidates for rare diseases, cancer, autoimmune and degenerative diseases, has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute.